Method for the enrichment of circulating tumor dna
A tumor, purpose technology, applied in the field of circulating tumor DNA, which can solve problems such as interference
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0102]Antibodies involved in specific binding to histone isoforms H3.1, H3.2, or H3t were biotinylated by the manufacturer's recommended method and immobilized on streptavidin-coated magnetic beads (Dynal). The beads were washed several times with loading buffer using a magnetic separation system. Serum or plasma obtained from a cancer patient is diluted with loading buffer and applied to the beads. Nucleosomes containing histone H3 variants were adsorbed to the beads. Other serum / plasma components remain in solution and are removed by magnetic separation. Wash the beads with buffer. At this point the histone H3 variant-containing nucleosomes are isolated onto beads. The ctDNA associated with the isolated nucleosomes is extracted by the phenol / chloroform method or other standard extraction methods. The extracted DNA can be analyzed for genetic or epigenetic characteristics of the cancer.
Embodiment 2
[0104] Antibodies involved in specific binding to histone isoforms H3.1, H3.2, or H3t were biotinylated by the manufacturer's recommended method and immobilized on streptavidin-coated magnetic beads (Dynal). The beads were washed several times with loading buffer using a magnetic separation system. Serum or plasma obtained from a cancer patient is diluted with loading buffer and applied to the beads. Nucleosomes containing histone H3 variants were adsorbed to the beads. Other serum / plasma components remain in solution and are removed by magnetic separation. Wash the beads with buffer. At this point the histone H3 variant-containing nucleosomes are isolated onto beads. The isolated nucleosomes are removed from the beads using elution buffer and analyzed by proteomic methods including mass spectrometry.
Embodiment 3
[0106] Circulating cell-free nucleosome levels were determined using a commercial (total) nucleosome ELISA from Roche in serum samples obtained from six patients with CRC preoperatively and at 6, 24, 48, 72 and 96 hours postoperatively , which uses common anti-nucleosomal core epitopes and tagged anti-dsDNA antibodies. The samples were then re-assayed but using anti-histone variants H3.1, H3.2 or H3t capture antibodies. Using a commercial ELISA, measured (total) nucleosome levels increased following surgical trauma, but for histone H3 variant-containing variants measured using assays employing anti-histone H3.1, H3.2 or H3t antibodies Nucleosomes are altered and diminished in response to surgery. result in image 3 displayed in .
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


